Robotic Rehab Devices in Texas
2 vendors serving Texas
Find robotic rehab devices vendors in Texas. MedIndexer lists vendors headquartered in Texas alongside nationwide vendors that serve Texas. Compare profiles, review service areas, and contact vendors directly — no middleman, no fees for buyers.
Top robotic rehab devices in Texas
HoustonBionics, Inc.
HoustonBionics is a medical device company specializing in at-home upper extremity rehabilitation for stroke and traumatic brain injury (TBI) survivors. The company's flagship product, ExoRehab X, is a clinical-grade robotic rehabilitation platform designed to support high-repetition, goal-directed practice of distal upper extremity movements—including wrist flexion/extension, radial/ulnar deviation, and forearm pronation/supination. The system provides interactive, gamified therapy with adaptive assistance or resistance based on patient effort, enabling users to complete 1,000+ repetitions per day. ExoRehab X integrates progress tracking via built-in sensors and is designed for use in clinical settings and at home, complementing rather than replacing clinician-guided care. FDA-registered as a Class I medical device, the platform leverages neuroplasticity principles and research from Rice University and Texas Medical Center partnerships. HoustonBionics partners with health systems and rehabilitation clinics to integrate ExoRehab X into post-discharge care protocols, targeting improved patient engagement, compliance, and functional recovery outcomes.
MicroTransponder Inc.
MicroTransponder Inc., operating under the brand Vivistim, manufactures FDA-approved breakthrough vagus nerve stimulation (VNS) therapy systems for post-stroke upper limb recovery. The Vivistim system is a wearable neuromodulation device designed to be paired with occupational and physical therapy to enhance neuroplasticity and improve hand and arm function in chronic ischemic stroke survivors. The device delivers targeted vagal stimulation during rehabilitation exercises and daily activities, clinically demonstrated to provide 2–3 times greater improvement in upper limb function compared to intensive therapy alone. FDA-cleared as a breakthrough device for safety and efficacy, the system targets a significant market of stroke survivors with persistent upper limb impairment. The company operates a patient qualification and enrollment model, working with rehabilitation specialists and therapy centers. Clinical evidence supports high user satisfaction (98%) and lasting functional improvements with sustained reduction in impairment. The company partners with leading stroke advocacy and occupational therapy organizations, indicating strong clinical and professional credibility in the neurorehabilitation space.